## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report identification of the natural anthraquinone emodin as a competitive inhibitor of KPC-2 carbapenemase via virtual screening and in vitro assays, with an IC50 of 24.4 µM. They propose a dual mechanism: direct active-site competition at Trp105 and Thr237 with secondary structural changes, and modulation of succinate dehydrogenase (SDH) activity and expression leading to metabolic perturbation. The combination of emodin and meropenem is claimed to be synergistic, to prevent resistance over 30 generations, and to reduce bacterial load and lung pathology in a mouse pneumonia model.
- **Visible evidence base** Abstract text only; no experimental details, numerical data beyond IC50 and log CFU reduction, statistical analyses, or methodological descriptions are provided
- **Missing materials affecting confidence** Full methods, all figures and tables, molecular dynamics simulation parameters and trajectories, binding affinity data, synergy assay details (checkerboard or time-kill), SDH activity assay specifics, transcriptional analysis data, resistance passage protocol, animal ethics and dosing details, histopathology images, and statistical reporting

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting dual-mechanism hypothesis for a natural product as a KPC-2 inhibitor and meropenem synergist. However, the evidence as summarized is insufficient to establish the mechanistic claims or the translational significance. The competitive inhibition mechanism is inferred from molecular dynamics without supporting kinetic or structural data. The SDH-mediated metabolic perturbation claim is presented without quantitative evidence linking it to the observed synergy. The in vivo efficacy is reported with a single log reduction value and no statistical context. The abstract is not currently sufficient to support the conclusions drawn.
- **Who would be interested in the results, and why** Researchers in antimicrobial resistance, particularly those focused on carbapenemase inhibitors and combination therapy; medicinal chemists interested in natural product scaffolds for enzyme inhibition; and investigators studying metabolic modulation as an antibacterial strategy. The potential to restore carbapenem activity against KPC-producing pathogens is of broad clinical relevance.
- **Major strengths** The study addresses a clinically urgent problem with a clear translational goal. The dual-mechanism hypothesis is intellectually interesting and, if rigorously supported, would represent a novel contribution. The inclusion of in vivo data, even if limited in the abstract, suggests an attempt to move beyond in vitro characterization. The resistance development assessment over 30 generations is a valuable addition.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Mechanistic evidence
  - **Claim pointer** "Molecular dynamics simulation and interaction analyses indicated that emodin competitively occupied the active site of KPC-2 at Trp105 and Thr237"
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** The claim of competitive inhibition is based solely on molecular dynamics simulation and interaction analyses. No experimental kinetic data, such as Lineweaver-Burk plots or Dixon plots, are presented to demonstrate competitive inhibition. The specific residues Trp105 and Thr237 are mentioned without supporting mutagenesis or structural data.
  - **Why it matters** Competitive inhibition is a specific kinetic mechanism that cannot be established by computational methods alone. The distinction between competitive and non-competitive or mixed inhibition has direct implications for the proposed mechanism of action and for future optimization of the compound.
  - **Resolution test** Provide enzyme kinetics data with varying substrate and inhibitor concentrations showing a characteristic competitive pattern, or co-crystallography or NMR structural evidence of emodin bound at the active site. Mutagenesis of Trp105 and Thr237 with loss of inhibition would further support the claim.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Mechanistic evidence
  - **Claim pointer** "emodin modulates succinate dehydrogenase (SDH) activity and its transcriptional expression, resulting in metabolic perturbation that renders bacteria susceptible to meropenem"
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** The abstract claims that SDH modulation is a causal link to meropenem susceptibility, but no data are presented to show the direction or magnitude of SDH activity changes, the transcriptional changes, or the metabolic consequences. The connection between SDH modulation and restored meropenem susceptibility is asserted without mechanistic evidence.
  - **Why it matters** This is a second, independent mechanism proposed alongside direct KPC-2 inhibition. If both mechanisms are claimed, each must be rigorously established. The SDH pathway is central to bacterial respiration and metabolic homeostasis, and off-target effects could confound the interpretation of synergy.
  - **Resolution test** Provide quantitative SDH activity assays, transcriptional data (e.g., qPCR or RNA-seq), and metabolomic profiling. Demonstrate that SDH modulation alone, in the absence of KPC-2 inhibition, is sufficient to restore meropenem susceptibility, or show that the effect is dependent on the proposed pathway.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** In vivo efficacy
  - **Claim pointer** "the combination therapy significantly reduced MEM usage, decreased the pulmonary bacterial load by 1.43 log CFU/g of model group, attenuated lung inflammation, and restored normal lung histology"
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** The in vivo results are reported with a single log reduction value and no statistical measures, group sizes, or comparator details. The claim of "significantly reduced MEM usage" is not quantified. Histological restoration is stated without supporting images or scoring criteria.
  - **Why it matters** The translational value of the study rests on the in vivo efficacy. Without proper statistical reporting and clear comparator groups, the clinical relevance cannot be assessed. The 1.43 log reduction, while potentially meaningful, requires context regarding the infection model, treatment regimen, and baseline bacterial load.
  - **Resolution test** Provide full in vivo methods including animal numbers, dosing schedules, statistical tests, and effect sizes. Include histopathology scoring and representative images. Report the MEM dose reduction as a percentage or fold-change with confidence intervals.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Reporting clarity
  - **Affected element** IC50 value
  - **Evidence pointer** Abstract text; location not provided
  - **Issue** The IC50 of 24.4 µM is reported without assay conditions, substrate concentration, or replicates. This limits comparability with other KPC-2 inhibitors.
  - **Required correction** Specify the assay buffer, substrate, enzyme concentration, and number of independent replicates. Report the IC50 with a confidence interval or standard deviation.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Terminology
  - **Affected element** "competitive" inhibition
  - **Evidence pointer** Abstract text; location not provided
  - **Issue** The term "competitive" is used in the title and abstract, but the evidence presented is computational. This overstates the certainty of the mechanism.
  - **Required correction** Use "putatively competitive" or "predicted to bind competitively" until experimental kinetic data are provided.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Structural interpretation
  - **Affected element** Secondary structure changes
  - **Evidence pointer** Abstract text; location not provided
  - **Issue** The claim that emodin binding results in "reduced alpha-helices and increased beta-sheets" is presented without context on how this relates to enzyme function or whether this is a general protein perturbation rather than a specific inhibitory mechanism.
  - **Required correction** Provide circular dichroism or other experimental structural data, and discuss how the observed secondary structure changes relate to catalytic activity.
  - **Concern ID** R1-m4
  - **Severity** Minor
  - **Axis** Resistance assessment
  - **Affected element** "No resistance development was observed over 30 generations"
  - **Evidence pointer** Abstract text; location not provided
  - **Issue** The resistance development claim lacks details on the bacterial strain, selection pressure, and whether the assessment was for emodin alone or the combination.
  - **Required correction** Specify the strain, passage conditions, and whether resistance was assessed against emodin, meropenem, or the combination. Report the MIC values across generations.
  - **Concern ID** R1-m5
  - **Severity** Minor
  - **Axis** Synergy quantification
  - **Affected element** "Synergistic effect" of emodin and meropenem
  - **Evidence pointer** Abstract text; location not provided
  - **Issue** The synergy is stated but not quantified. No fractional inhibitory concentration index or time-kill data are provided.
  - **Required correction** Report the FICI value or provide time-kill curves with statistical analysis to support the synergy claim.

## Technical failings that need to be addressed before the case is established
- R1-M1: Competitive inhibition mechanism not experimentally established
- R1-M2: SDH-mediated metabolic perturbation as a causal mechanism not supported by data
- R1-M3: In vivo efficacy claims lack statistical and methodological detail

## Assessment against Nature-style criteria
- **Originality** The dual-mechanism hypothesis combining direct enzyme inhibition with metabolic modulation is somewhat novel, but the individual components are not unprecedented. The originality is moderate and would depend on the rigor of the mechanistic evidence.
- **Scientific importance** The clinical problem is important, and a natural product that restores carbapenem activity would be valuable. However, the importance of the specific findings cannot be fully assessed without stronger mechanistic and in vivo data.
- **Interdisciplinary readership** The topic bridges medicinal chemistry, microbiology, and infectious disease, which could attract a broad audience. The abstract is written in a way that is accessible to nonspecialists, but the mechanistic claims require more technical support.
- **Technical soundness** The technical soundness is currently inadequate based on the abstract alone. The computational and in vitro data are not sufficiently detailed, and the in vivo results lack statistical rigor.
- **Readability for nonspecialists** The abstract is generally readable, but the mechanistic claims are presented with insufficient context for nonspecialists to evaluate their validity.

## Recommendation posture
Currently not established from the provided evidence. The abstract presents an interesting hypothesis but lacks the experimental detail required to support the mechanistic and translational claims. The authors should be encouraged to provide full kinetic, structural, and in vivo data to substantiate the conclusions. A revised manuscript with complete experimental evidence could be reconsidered.